How we improved the treatment of Hodgkin lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login